Dashboard · Pharmaceuticals stocks · AUROPHARMA
75
JayScore

Aurobindo Pharma Limited

AUROPHARMA Pharmaceuticals
High Conviction Grade A+ 68% confidence
Score computed at ₹1,823.20 · 16 Nov 2026
Research signals 0 positive · 8 cautionary of 8
NSE
JayScore
75
vs
Sector signal
6
75
Aurobindo Pharma Limited AUROPHARMA High Conviction
Get notified when this stock's JayScore changes
Free account — score alerts, daily research picks, morning plan and portfolio tracker.
Sign Up Free Sign In
About Aurobindo Pharma Limited

Aurobindo Pharma Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.05 lakh crore. The company reports ROE of 10.7%, a net profit margin of 10.8%. Revenue grew +23.9% year-over-year. Promoter holding stands at 54.8%, with FII participation at 29.6%.

Pharmaceuticals sector signal: 6/100 — below-average — fewer than 40% of sector peers are trading above their EMA 20.
JayScore 75/100 indicates a strong research signal — multiple technical and fundamental factors are aligned positively. JayScore is a quantitative index — not investment advice. Learn how it's calculated →
JaySense Research View · quantitative signals only · not investment advice
High Conviction

Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). The breakout is happening on lighter-than-normal trading — needs confirmation (below-average volume on breakout bar). Yesterday's candle shape suggests buyers took control (✅ Bullish Engulfing — bullish reversal pattern). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Price is right at the ceiling of this year's range — a close above would be a significant breakout (at 52W high zone). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).

Positive Signals
Price is trending above key moving averages
Watch Points
Fundamental score is weak relative to benchmark
Valuation appears stretched on current metrics
Institutional activity is low or declining
Research Score Insight

Aurobindo Pharma Limited scores 75/100 (High Conviction Research Signal). The strongest signals are Trend (14/100) and Momentum (13/100). The weakest dimension is Institutional Activity (1/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.

Trend 14 Momentum 13 Volume 4 Fundamental 2 Valuation 2 Growth 6 Institutional 1 Sector 6 Risk 4
Research Intelligence Free Account Required
0 positive · 9 risk signals identified 4 / 9 signals converging
Downtrend active — price has broken below key moving averages
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels

8 more research signals — available free with a JaySense account

Get Free Access Sign in
Sector & Institutional Activity Free Account Required
Sector Health
6.4000/100
Sector Rank
#3 of 12
FII Activity
Net Buying
FII net buyers ₹840 Cr over last 10 sessions — institutional accumulation in progress
DII activity supportive — domestic funds adding to position

Sector peer rank, FII/DII trend & institutional activity — free with a JaySense account

Get Free Access Sign in
Score Analysis
Trend
14
Weak
Price vs moving averages · trend structure
Momentum
13
Weak
MACD · RSI · rate-of-change
Volume
4
Weak
Volume strength · accumulation vs distribution
Fundamental
2
Weak
Margins · returns · debt ratios
Valuation
2
Weak
PE · PB · multiples vs sector
Growth
6
Weak
Revenue & profit growth YoY
Sector
6
Weak
Sector relative strength vs market
Risk
4
Weak
Volatility · beta · drawdown risk
Institutional
1
Weak
FII / DII participation & block deals
Signal convergence: 4 / 9 dimensions aligned · Moderate convergence
Score Trend (Last 30 Scores)
Fundamentals
Market Cap
₹1.05 L Cr
P/E Ratio
26.4
P/B Ratio
2.66
EPS (TTM)
69.05
ROE
10.7%
ROCE
—
Net Profit Margin
10.8%
Debt / Equity
21.9
Revenue Growth YoY
23.9%
Profit Growth YoY
33.9%
Promoter Holding
54.8%
FII Holding
29.6%
Dividend Yield
0.8%
Company Profile
Aurobindo Pharma Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.05 lakh crore. The company reports ROE of 10.7%, a net profit margin of 10.8%. Revenue grew +23.9% year-over-year. Promoter holding stands at 54.8%, with FII participation at 29.6%.
Corporate Actions
Corporate Actions Source: NSE
Recent History
₹7.00 / share
11 Nov 2026
Dividend
Related Research — Same Sector
Stock Score Signal
SUNPHARMA
Sun Pharmaceutical Industries Limited
84 High Conviction
APOLLOHOSP
Apollo Hospitals Enterprise Limited
73 High Conviction
DIVISLAB
Divi's Laboratories Limited
72 High Conviction
CIPLA
Cipla Limited
69 Positive Setup
GLENMARK
Glenmark Pharmaceuticals Limited
60 Positive Setup
How JaySense scores stocks Full stock screener
Disclaimer: JaySense scores are research outputs based on technical and fundamental signals. They are not buy/sell recommendations and do not constitute investment advice. Past score performance does not guarantee future returns. Please do your own research or consult a SEBI-registered investment advisor before making any investment decision. JaySense is not SEBI-registered. Use this platform for educational and research purposes only.